Business Information
The company's principal activity is to develop and commercialize proprietary technology applicable to implement the final stage delivery of therapeutic single stranded dna molecules in cells. The technology of the company prevents genetically diseased cells from manufacturing harmful proteins, thereby preventing disease. It owns patented intracellular expression system technology (cygxes) to produce any desired sequence-specific, ssdna molecules (odn) in individual cells for the purpose of triplex, antisense, catalytic dna, and aptamer applications. It seeks to market and license its technology to biotechnology companies owning dna sequences in the human genome and to assist in their determination of the function and purpose of these sequences. The company primarily operates in the United States of America. The company is in its development stage.
|
|
Name |
Title
|
Email
|
| Malcolm Skolnick | Chmn., CEO, Pres. | N/A | | Frank Vazquez | COO, Exec. VP | N/A | | Greg Taylor | VP - Finance, Administration, CFO | N/A | | Yin Chen | Chief Scientific Officer, VP - Research, Development | N/A | | Alan Gewirtz | Member - Scientific Advisory Board | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 77 | (4,096) | | 2005 | N/A | (3,533) | | 2004 | N/A | (2,365)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
